- Stocks
- Pharma & Healthcare
- Accretion Nutra
Accretion Nutra share price
NSE: ANLPharma & HealthcareDrug Manufacturers - Specialty & Generic
Accretion Nutra at a glance
With a market capitalisation of ₹184 Cr, it ranks 2325th by market cap among the 4,183 NSE companies Pivot tracks (a small-cap company by SEBI's rank bands). It belongs to the Pharma & Healthcare sector; its industry is Drug Manufacturers - Specialty & Generic.
Its return on equity was 48.8% in FY25. Promoters held 73.48% of the company as of 30 Jun 2026.
Key numbers
- Market cap
- ₹184 CrRank 2325 on NSE
- Price to book
- 0×FY25
- ROE
- 48.8%FY25
- ROCE
- 51.2%FY25
- Debt to equity
- 0.72FY25
- Net profit margin
- 16.3%FY25
- Book value / share
- ₹109.83FY25
Returns to 19 Oct 2026
| Period | 1 day | 1 week | 1 month | 3 months | 1 year |
|---|---|---|---|---|---|
| Price change | — | — | — | — | — |
Accretion Nutra financials
| Item | FY22 | FY23 | FY24 | FY25 |
|---|---|---|---|---|
| Revenue | ₹1 Cr | ₹3 Cr | ₹5 Cr | ₹16 Cr |
| Operating profit | −₹0 Cr | ₹0 Cr | ₹1 Cr | ₹3 Cr |
| Net profit | −₹0 Cr | ₹0 Cr | ₹1 Cr | ₹3 Cr |
| EPS (₹) | −₹0.11 | ₹7.79 | ₹22.83 | ₹71.91 |
| Cash from operations | ₹0 Cr | ₹1 Cr | ₹0 Cr | −₹2 Cr |
| Total debt | ₹2 Cr | ₹1 Cr | ₹1 Cr | ₹2 Cr |
| Shareholders' equity | −₹0 Cr | ₹0 Cr | ₹1 Cr | ₹5 Cr |
Accretion Nutra shareholding pattern
| Holder | 2 Feb 2026 | 31 Mar 2026 | 30 Jun 2026 |
|---|---|---|---|
| Promoters | 73.48% | 73.48% | 73.48% |
| Foreign institutions | 6.04% | 1.08% | 1.08% |
| Domestic institutions | 6.51% | 7.00% | 6.10% |
| Non-institutions | 13.98% | 18.44% | 19.34% |
Accretion Nutra vs peers
The listed Pharma & Healthcare companies nearest to Accretion Nutra by market capitalisation.
Ask anything about Accretion Nutra
Pivot answers on the live chart with evidence you can check, and tests strategies against ANL's own history. Try: “Why has ANL moved over the last three months?” · “Backtest a 50-day moving-average crossover on ANL over five years” · “Compare ANL with AASHKA on margins and valuation”
Frequently asked questions about Accretion Nutra
What is the market cap of Accretion Nutra?
Accretion Nutra's market capitalisation is ₹184 Cr (₹184 Cr) at the 19 Oct 2026 close, ranking 2325th among the NSE companies Pivot tracks.
What is the ROE and ROCE of Accretion Nutra?
Return on equity was 48.8% in FY25 and return on capital employed was 51.2% in FY25 (standalone figures).
Is Accretion Nutra a debt-free company?
No. Accretion Nutra's debt-to-equity ratio was 0.72 in FY25, with total debt of ₹2 Cr.
What is the shareholding pattern of Accretion Nutra?
As of 30 Jun 2026: promoters 73.48%, foreign institutions 1.08%, domestic institutions 6.10%, non-institutions 19.34%.
Who are Accretion Nutra's competitors?
The listed Pharma & Healthcare companies closest to Accretion Nutra by market cap are Aashka Hospital, OXYGENTA PHARMA, Earkart, Novelix Pharma, Medico Remedies and Take Solutions.
Is Accretion Nutra a good stock to buy?
Pivot does not give buy or sell recommendations. This page sets out Accretion Nutra's price history, valuation, profitability, quarterly results and ownership so you can judge it yourself, and Pivot's chart lets you test a strategy on ANL against its own history before risking money. This is analysis, not financial advice.
Sources and method
Prices: NSE daily closes to 19 Oct 2026 (returns and ratios at the 19 Oct 2026 close). Fundamentals: company filings via Moneycontrol, consolidated where available. Shareholding: exchange shareholding-pattern filings. The 52-week range uses intraday highs and lows; the chart marks closing prices. P/E is the last close over trailing twelve-month EPS. Market-cap rank is among the 4,183 NSE companies Pivot tracks; SEBI's bands call the top 100 large-cap and the next 150 mid-cap. Figures marked “—” are not available rather than zero. This is analysis, not financial advice.
More: all Pharma & Healthcare stocks · companies starting with A · all NSE stocks · this page as text